Compare Gilead Sciences, Inc. (GILD) vs Harley-Davidson Inc (HOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Harley-Davidson Inc — how do they compare? Gilead Sciences, Inc. trades at $133.3 (market cap $163.51B), while Harley-Davidson Inc trades at $26.76 (market cap $2.73B). The key difference: Gilead Sciences, Inc. is far larger — about 59.9× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| GILD | HOG | |
|---|---|---|
Market Cap | $163.51B | $2.73B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $31.03 |
52-Week Low | $108.22 | $17.19 |
Enterprise Value | $178.05B | $3.13B |
Dividend Yield | 2.49% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Harley-Davidson (HOG) trades at $25.11, down 1.1% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. Recent earnings have been volatile, with Q1 2026 missing estimates despite revenue growth. The company is executing a turnaround strategy including U.S. production reshoring and cost cuts, reflected in improving cash flow trends but declining revenue and margins since 2022.
The outlook hinges on margin recovery from operational reset initiatives, but risks include competitive pressures and execution challenges. Analysts are cautious with 65.7% hold ratings, though some see value at current valuations. The stock faces near-term pressure with consensus price target below current levels, requiring successful turnaround execution for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →
